An association study of ADSS gene polymorphisms with schizophrenia

Fuquan Zhang¹, Pak C Sham², Hua Fan³, Yong Xu¹, Xuezhu Huang¹, Honcheong So², Yuqing Song² and Pozi Liu*¹

Address: ¹Institute of Neurological disorders, Tsinghua University; Department of Psychiatry, Yuquan Hospital, Tsinghua University, Beijing, 100049, PR China, ²Department of Psychiatry, University of Hong Kong, Hong Kong, PR China and ³Department of Psychiatry, Beijing Anding Hospital, Capital Medical University, Beijing, PR China

Email: Fuquan Zhang - zhfq@tsinghua.edu.cn; Pak C Sham - pcsham@hkucc.hku.hk; Hua Fan - iy4232925@163.com; Yong Xu - xuyongsmu@yahoo.com.cn; Xuezhu Huang - huangxuezhu@tsinghua.edu.cn; Honcheong So - hcs0910@gmail.com; Yuqing Song - songyq293@hotmail.com; Pozi Liu* - liupozi@tsinghua.edu.cn

* Corresponding author

Abstract

Background: Adenylosuccinate synthase (ADSS) catalyzes the first committed step of AMP synthesis. It was suggested that the blood-derived RNA of ADSS was down-regulated in schizophrenia (SZ) and one of the eight putative biomarker genes to discriminate SZ from normal controls. However, it remains unclear whether the reduction of ADSS RNA is due to the polymorphisms of the gene or not.

Methods: We attempted to examine the association of ADSS gene with schizophrenia in a Chinese population of 480 schizophrenics and 502 normal controls. Genotyping was performed by the Sequenom platform.

Results: The 6 marker SNPs (rs3102460, rs3127459, rs3127460, rs3127465, rs3006001, and rs3003211) were genotyped. The frequencies of alleles, genotypes, and haplotypes were tested between cases and controls. There was no significant difference of genotypic, allelic, or haplotypic distributions of the 6 SNPs between the two groups.

Conclusion: Our data did not support ADSS gene as a susceptibility gene for SZ in Chinese Han population. Large sample size study is needed to validate or replicate our association study, especially from other ethnic populations.
cated in the susceptibility of SZ with independent replicative evidences from multiple populations [2,4,5].

Following the searching of genetic basis for the mechanism of SZ, some lines of evidences have also emerged from other kinds of biomarkers, such as level of gene expression. Recent advances have facilitated the use of circulating blood to conduct genomic analyses of human disease [6,7]. Vawter et al. [8] identified nine genes that were differentially expressed between SZ patients and controls. Thereafter, by analyzing the blood-derived RNA from 74 samples, linear and non-linear combinations of eight putative biomarker genes (APOBEC3B, ADSS, ATM, CLC, CTBP1, DIDO1, CXCL1, and S100A9) were able to discriminate among schizophrenia, bipolar disorder, and control samples [9], with an overall accuracy of 95%-97%. None of these genes have yet been investigated for their association or linkage disequilibrium with SZ.

Among them, ADSS is down-regulated in the SZ patients. The de novo biosynthesis of AMP from IMP involves two steps, with the first step catalyzed by ADSS followed by adenylsuccinate lyase catalyzing the second step [10]. The gene encoding ADSS maps to 1cen-q12, the chromosomal loci previously linked to schizophrenia in meta-analysis [11,12]. The sequence of ADSS gene is 44 kb in length, with 13 exons and 12 introns.

However, it is unknown whether the alteration in ADSS expression is due to defect of the gene, or secondary to other disease-related factors. In order to address this issue, and to test the hypothesis that sequence variations of ADSS gene influence the risk for the disease, we conducted a case-control association study on 6 SNPs (rs3102460, rs3127459, rs3127460, rs3127465, rs3006001 and rs3003211) to check the allelic and haplotypic association of ADSS with SZ. The average estimated heterozygosity of these SNPs is 0.37, and they span 36 Kb nucleotides in the 44 Kb pairs of ADSS.

Genotyping

In view of information from dbSNP [13], according to the location and the heterozygosity of SNP, we selected 6 SNPs from intron-11 (rs3102460), intron-6 (rs3127459), intron-4 (rs3127460), intron-1 (rs3127465, rs3006001 and rs3003211) to check the allelic and haplotypic association of ADSS with SZ. The length of the amplicons for SNP capture ranged from 60 to 120 base pairs (bp). Following genomic amplification of the target regions, PCR products were treated with shrimp alkaline phosphatase for 20 minutes at 37°C to dephosphorylate any residual nucleotides and to prevent their future incorporation and interference with the primer extension assay. Extension primers, DNA polymerase, and a cocktail mixture of deoxynucleotides (dNTPs) and dideoxynucleotide triphosphates (ddNTPs) were added to each mix. These were then followed by cycles of homogeneous MassEXTEND™ (hME) reaction probed by the extension primers for each SNP. The MassARRAY™ typer software version 3.1 was then used to read out the extended mass and assign the genotype call. Quality control criteria included genotype call rate of >80%, less than 1 duplicate errors (5 duplicates in each 96 well-plate), and significant Hardy-Weinberg disequilibrium.

Statistical analyses

Hardy-Weinberg equilibrium, genotype and allele frequencies between cases and controls for ADSS markers were tested using PLINK [14]. Linkage disequilibrium (LD) between markers was tested by Haplview [15]. Haplotype analyses were performed using UNPHASED [16] as well as SHEsis [17]. UNPHASED contains a suite of programs for association analysis of haplotype data, including COCAHPE and QTPHASE. The most significant p-value in the haplotype analysis was corrected for multiple testing by running 1000 permutations of the data by COCAHPE. In each permutation, the ‘case’ and ‘control’ labels were randomly re-assigned among subjects and the best p value were stored to provide an empirical frequency distribution. The program employs the expectation-maximization (EM) algorithm to estimate haplotypes with unknown phases. Individuals with missing genotype information at one or more loci were excluded from analyses by UNPHASED. Haplotypes with frequencies <3% in the whole sample were considered be to be rare and excluded.
Results

Genotype and allele distributions of SNPs

The allele and genotype frequencies of 6 SNPs among 480 SZ patients and 502 healthy controls were shown in Table 1. The genotypic distributions of these six polymorphisms did not deviate significantly from Hardy-Weinberg Equilibrium in both patients and controls (p > 0.05). There was no significant difference in genotype or allele frequencies between cases and controls.

Patterns of LD

The patterns of Pair-wise LD between neighbouring SNPs were shown in Figure 1. Fairly tight linkage disequilibrium was observed in any pair of the SNPs and the six markers were in strong LD.

Haplotypes of the six markers

As can be seen in Table 2, there is no global or individual significant difference for 6-marker haplotype in our sample. Individual haplotype tests were performed by evaluating the difference in risk between a specific haplotype and all others grouped together. Also, we obtained no significant difference in haplotype frequencies for two-, three-, four-, or five-marker analyses between patients and controls (data not shown).

Discussion

Although genome-wide scan for linkage in multiply-affected families with schizophrenia has consumed lots of money and effort, no forms of schizophrenia following Mendelian inheritance patterns have yet been discovered [2]. Numerous evidences show that multiple genes of small effect contribute to increasing liability to SZ, which seems to have a cumulative effect, and putatively, threshold effect. On the other hand, the study on schizophrenia has confirmed the vital role of genes in its etiology, but has not so far identified the relationship between observed genetic risks and specific DNA variants, protein alterations, or biological processes [18], nor was diagnostic neuropathology, or even unequivocally replicated associations with the same alleles or haplotype within each gene identified [4].

Table 1: Genotypic and allelic distributions of the ADSS SNPs in cases and controls

| SNP        | Genotype frequency (%) | p (df = 2) | Allele frequency (%) | p (df = 1) | OR(95%CI) | HW p |
|------------|------------------------|------------|----------------------|------------|-----------|------|
|            | CC                     | CT         | TT                   | C          | T         |      |
| R3127460   | ca441                  | 48(10.9)   | 176(39.9)            | 217(49.2)  | 272(30.8) | 0.344| 1.1(0.9–1.35)| 0.181|
|            | co443                  | 37(8.4)    | 181(40.9)            | 225(50.8)  | 255(28.8) | 0.344| 1(0.9–1.35)   | 1    |
|            | AA                     | AT         | TT                   | A          | T         |      |
| R3127459   | ca476                  | 26(5.5)    | 170(35.7)            | 280(58.8)  | 222(23.3) | 0.212| 0.88(0.71–1.08)| 0.484|
|            | co499                  | 36(7.2)    | 185(37.1)            | 278(55.7)  | 257(25.8) | 0.212| 0.88(0.71–1.08)| 1    |
|            | TT                     | AT         | AA                   | T          | A         |      |
| R3127460   | ca477                  | 12(2.5)    | 149(31.2)            | 316(66.2)  | 713(18.1) | 0.487| 0.92(0.74–1.16)| 0.353|
|            | co501                  | 16(3.2)    | 162(32.3)            | 323(65.5)  | 194(19.4) | 0.487| 0.92(0.74–1.16)| 0.477|
|            | CC                     | CT         | TT                   | C          | T         |      |
| R3127456   | ca470                  | 11(2.3)    | 144(30.6)            | 315(67.0)  | 166(17.7) | 0.551| 0.93(0.74–1.18)| 0.340|
|            | co489                  | 16(3.3)    | 151(30.9)            | 322(65.8)  | 183(18.7) | 0.551| 0.93(0.74–1.18)| 0.882|
|            | CC                     | AC         | AA                   | C          | A         |      |
| R3006001   | ca475                  | 12(2.5)    | 146(30.7)            | 317(66.7)  | 170(19.7) | 0.409| 0.91(0.72–1.14)| 0.434|
|            | co496                  | 16(3.2)    | 160(32.3)            | 320(64.5)  | 192(19.4) | 0.409| 0.91(0.72–1.14)| 0.565|
|            | GG                     | AG         | AA                   | G          | A         |      |
| R3003211   | ca436                  | 50(11.5)   | 171(39.2)            | 215(49.3)  | 271(31.1) | 0.401| 1.09(0.89–1.34)| 0.093|
|            | co453                  | 44(9.7)    | 177(39.1)            | 232(51.2)  | 265(29.2) | 0.401| 1.09(0.89–1.34)| 0.256|

ca = case, co = control. HW = Hardy-Weinberg
whole genome analysis (e.g. 1q, 6p, 6q, 15q) [19]. Recently, many polymorphisms located in regions of chromosome 1 were reported as susceptibility loci for SZ [5,20], including risk markers in 1q44 [21] 1q43 [22], both of which lie adjacent to ADSS.

Although whole genome linkage scan and functional studies have implied several very promising positional candidates, such as NRG1 [23], DTNBP1 [24], COMT [4], DISC1 [25], DAOA [26,27], RGS4 [28] and so on [5,23,28-31], there may be several genes that play subtle or weak roles in the pathogenesis of SZ, making it difficult to investigate by traditional approaches. To tackle this problem, another approach to finding potential candidate genes is using microarray technology to examine RNA of a gene which shows differential expression between patients and controls, by which ADSS gene was suggested as one of candidates for SZ.

Functionally, the ADSS catalyzes the key step in the synthesis of AMP, which influences the energy metabolism through the purine nucleotide cycle (PNC) and the AMPK (AMP-activated protein kinase) pathway [32]. The reaction is as follows: IMP+L-aspartate+GTP ↔ adenylosuccinate+GDP+phosphate. Genetically, ADSS gene resides in the susceptibility loci and the blood-derived RNA of ADSS was among the eight genes with putatively differential diagnostic power for SZ. Hereto, there is no genetic association study of ADSS with SZ, and the mechanism of hypo-expression of ADSS is elusive, nevertheless, it suggested that ADSS gene was possibly involved in the genetic architecture of SZ, for genetic variation or polymorphisms can dominate gene expression as well as confer disease risk to human beings.

Our study is an exploration study to seek the trait’s genetic basis following a clue from RNA alterations in SZ. However, the data did not display any statistically significant difference for both the allelic and genotypic distribution between cases and controls. Although haplotype analysis is a powerful tool for identifying candidate genes for complex disease, there was no positive finding in current study. Therefore, our result does not support the association of ADSS gene with SZ. It implies that down-regulation of ADSS in patients may not result from the gene’s polymorphisms.

One common issue in the study of complex diseases is the limited sample size, resulting in inadequate power to detect association. With regard to our data, assuming the frequency of risk allele in controls to be 0.5, our sample of 480 cases and 502 controls is able to detect an odds ratio (OR) of 1.43 or above with 80% power [33]. It is possible that false-negative results may arise from lack of power. Another issue of researches in multifactor diseases is the underlying high degree of genetic heterogeneity of perplexing phenotype. SZ is not simply defined by several major genes but rather evolves from addition or potentiation of a specific cluster of genes, which subsequently determine the genetic vulnerability of an individual. Thus,
there are likely different genes or sets of genes associated with schizophrenia disorders in different populations [34]. It is necessary to validate or replicate our association results using independent samples especially from other ethnic populations.

It’s been suggested that the promoter and 5’ flanking region of murine ADSS gene possessed regulatory elements that could influence its expression [35]. In addition, ADSS has several splicing variants. Therefore, the examinations of SNPs within 5’ flanking region and those potentially affecting splicing may be valuable in further study.

Conclusion
In conclusion, our data did not support ADSS gene as a susceptibility gene for SZ in Chinese Han population. Further study on genetic regulation, neural network, or epigenetics will facilitate to elucidate the role of ADSS in SZ.

Abbreviations
APOBEC3B: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B; ATM: ataxia telangiectasia mutated; CLC: Charcot-Leyden crystal protein; COMT: catechol-O-methyltransferase; CTBP1: C-terminal binding protein 1; CXCL1: chemokine (C-X-C motif) ligand 1; DAOA: D-amino acid oxidase activator; DIO1: death inducer-obliterator 1; DISC1: disrupted in schizophrenia 1; DTNBP1: dystrobrevin binding protein 1; NRG1: neuregulin 1; RGS4: regulator of G-protein signaling 4; S100A9: S100 calcium binding protein A9.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SPC designed and coordinated the study. SYQ, XY, and HXZ drafted the manuscript. FH, SHC and HXZ participated in data management and statistical analysis. LPZ participated in the supervision of the project. All authors read and approved the final manuscript.

Acknowledgements
The project was funded by National Natural Science Foundation of China (30570430) (LPZ, ZFQ), Tsinghua-Yu-Yuan Medical Sciences Fund (LPZ, ZFQ), and Collaboration Grant from the Wellcome Trust for funding (SPC, SHC, SYQ).

References
1. Saha S, Chant D, Welham J, McGrath J: A systematic review of the prevalence of schizophrenia. PLoS Med 2005, 2:e141.
2. Kirov G, O DM, Owen MJ: Finding schizophrenia genes. J Clin Invest 2005, 115:1440-1448.
3. Cardno AG, Gottesman II: Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet 2000, 97:1-17.
4. Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10:40-65.
5. Gregos JA, Gerber DJ: Schizophrenia susceptibility genes: emergence of positional candidates and future directions. Trends Pharmacol Sci 2006, 27:226-233.
6. Nishimura Y, Martin CL, Vazquez-Lopez A, Spence S, Alvarez-Remuerto AI, Sigman M, Steinfeld C, Pellegri-S, Schanen NC, Warren ST, Geschwind DH: Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. Hum Mol Genet 2007, 16:1682-1698.
7. Vaherpeso P, Kakko A, Saksela O, Aittomaki K, Aaltonen LA: Blood-derived gene-expression profiling in unravelling susceptibility to recessive disease. J Med Genet 2007, 44:718-720.
8. Yawner MP, Ferran E, Galle B, Cooper K, Bunney WE, Byerley W: Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr Res 2004, 67:41-52.
9. Tsuang MT, Nossova N, Yager T, Tsuang MM, Guo SC, Shyu KG, Glatt SJ, Liew CC: Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 2005, 131B:1-5.
10. Mehrrota S, Balaram H: Kinetic characterization of adenylosuccinate synthase from the thermophilic archaea Methanocaldococcus jannaschii. Biochemistry-Us 2007, 46:1281-12832.
11. Badner JA, Gershon ES: Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 2002, 7:405-411.
12. Lewis CM, Levinson DF, Wise LH, Delisi LE, Straub RE, Hovatta I, Williams NM, Schwan SG, Pulver AE, Farsony SV, Brzustowicz LM, Kaufmann CA, Garver DL, Gurting HM, Lindholm E, Coon H, Moises HW, Byerley W, Shaw SH, Mesen A, Sherrington R, O NF, Walsh D, Kendler KS, Ekelund J, Paunio T, Lonnqvist J, Feltonen L, O DM, Owen MJ, Wildenauer DB, Maier W, Nestadt G, Blouin J, Antonarakis SE, Mowry BJ, Silverman JM, Crowe RR, Cloninger CR, Tsuang MT, Malapina D, Harkavy-Friedman JM, Svrakic DM, Basset AS, Holcomb J, Kalsi G, McQuillan A, Brynjolfsson J, Sigmundsson T, Petursson H, Jazin E, Zoega T, Helgason T: Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 2003, 73:34-48.
13. SNP database of NCBI [http://www.ncbi.nlm.nih.gov/SNP/]
14. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de BP, Daly MJ, Shach PM: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007, 81:559-575.
15. Barrett JC, Fry B, Maller J, Daly MJ: Haplovie: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
16. Dudbridge F: Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003, 25:115-121.
17. Shi YY, He L: SHESis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005, 15:97-98.
18. Riley B, Kendler KS: Molecular genetic studies of schizophrenia. Eur J Hum Genet 2006, 14:669-680.
19. Straub RE, Weinberger DR: Schizophrenia genes – famine to feast. Biol Psychiatry 2006, 60:81-83.
20. Norton N, Williams H, Owen MJ: An update on the genetics of schizophrenia. Curr Opin Psychiatry 2006, 19:158-164.
21. Saviouk V, Chow EW, Basset AS, Brzustowicz LM: Tumor necrosis factor promoter haplotype associated with schizophrenia reveals a linked locus on 1q44. Mol Psychiatry 2005, 10:375-383.
22. Kempisty B, Sikora J, Capistrata M, Szczepankiewicz A, Czerski P, Hauser J, Jagodziński PP: MTHFD 1958G>A and MTR 2756A>G polymorphisms are associated with bipolar disorder and schizophrenia. Psychiatr Genet 2007, 17:177-181.
23. Harrison PJ, Law AJ: Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006, 60:132-140.
24. Li D, He L: Association study between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia: a meta-analysis. Schizophr Res 2007, 96:112-118.
25. Ishizuka K, Paek M, Kamiya A, Sawa A: A review of Disrupted-In-Schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental conditions. *Biol Psychiatry* 2006, 59:1189-1197.

26. Detera-Wadleigh SD, McMahon FJ: G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. *Biol Psychiatry* 2006, 60:106-114.

27. Li D, He L: G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies. *Genetics* 2007, 175:917-922.

28. So HC, Chen RY, Chen EY, Cheung EF, Li T, Sham PC: An association study of RGS4 polymorphisms with clinical phenotypes of schizophrenia in a Chinese population. *Am J Med Genet B Neuropsychiatr Genet* 2008, 147B:77-85.

29. Millar JR, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, Malloy MP, Chubb JE, Huston E, Baillie GS, Thomson PA, Hill EV, Brandon NJ, Rain JC, Camargo LM, Whiting PJ, Houslay MD, Blackwood DH, Muir WJ, Porteous DJ: DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. *Science* 2005, 310:1187-1191.

30. Harrison P. Schizophrenia susceptibility genes and neurodevelopment. *Biol Psychiatry* 2007, 61:1119-1120.

31. Tan HY, Chen Q, Sust S, Buckholz JW, Meyers JD, Egan MF, Mattay VS, Meyer-Lindenberg A, Weinberger DR, Callicott JH: Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. *Proc Natl Acad Sci USA* 2007, 104:12536-12541.

32. Li X, Zhu Z, Mo D, Wang H, Yang S, Zhao S, Li K: Comparative molecular characterization of ADSS1 and ADSS2 genes in pig (Sus scrofa). *Comp Biochem Physiol B Biochem Mol Biol* 2007, 147:271-277.

33. Dupont WD, Plummer WD: Power and sample size calculations for studies involving linear regression. *Control Clin Trials* 1998, 19:589-601.

34. Braff DL, Freedman R, Schork NJ, Gottesman II: Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. *Schizophr Bull* 2007, 33:21-32.

35. Lewis AL, Guicherit OM, Datta SK, Hanten GR, Kellems RE: Structure and expression of the murine muscle adenylotrussinate synthetase gene. *J Biol Chem* 1996, 271:22647-22656.